GENE ONLINE|News &
Opinion
Blog

2025-11-26|

Study Explores Use of Digital Twin Technology to Enhance Safety and Risk Assessment in Nuclear Power Plants

by GOAI
Share To

A recent study has examined the use of digital twin technology in nuclear power plants, highlighting its potential to improve safety management and risk assessment throughout a plant’s lifecycle. The research, conducted by H. Yu, explores how this advanced system can simulate real-time operations and predict potential issues, offering a comprehensive tool for enhancing nuclear safety protocols.

Digital twin technology creates virtual replicas of physical systems, enabling operators to monitor and analyze performance under various conditions without disrupting actual operations. According to the study, this approach allows for more accurate predictions of equipment behavior and system responses during critical scenarios. By integrating real-time data with predictive modeling, the technology provides insights that could help identify vulnerabilities and optimize maintenance schedules. Researchers suggest that such advancements may contribute significantly to improving operational reliability and reducing risks in nuclear energy facilities.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top